Illicit fentanyl use exceeds medical use
Analysis based on 6 articles · First reported Aug 24, 2026 · Last updated Aug 27, 2026
The study underscores the severity of the illicit fentanyl crisis, potentially influencing public health policy and funding allocations toward addiction treatment and overdose prevention. Pharmaceutical companies and healthcare providers may face increased regulatory scrutiny and shifts in prescribing practices, while public health agencies could see heightened attention and resource deployment.
A large retrospective cohort study published in eClinicalMedicine on August 14, 2026, analyzed electronic health records from Epic Cosmos, covering nearly 300,000 patients who tested positive for fentanyl between 2015 and 2023. The study found that illicit-source fentanyl use (71.1% of the cohort) is more than twice as common as medical-source use (28.9%). Illicit users faced a two- to three-fold higher risk of nonfatal overdose, abuse, and dependence within 30 days of initiation, and by 2023, the prevalence of nonfatal overdose was 18.6% among illicit users versus 4.3% among medical users. The study also identified geographic disparities, with United States — Ohio having the highest proportion of illicit fentanyl users (12.2%), followed by United States — Massachusetts State Police (10.5%) and United States — California (8.8%). The research was led by Zhang Ping and Seungyeon Lee at Ohio State University, with co-authors from Harvard Medical School, and was funded by the United States — National Institute on Drug Abuse and the United States — National Science Foundation. The findings highlight the growing threat of illicit fentanyl and suggest that current opioid regulations focused on medical sources may be insufficient, calling for expanded toxicology screening and public health interventions.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard